The stock of Apogee Therapeutics Inc. (NASDAQ: APGE) has decreased by -6.12 when compared to last closing price of 51.50.Despite this, the company has seen a loss of -16.70% in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-28 that Apogee (APGE) surges 95.6% in a month after reporting positive interim results from its phase I study for APG777 to treat AD. The company plans to initiate a phase II study for the same indication.
Is It Worth Investing in Apogee Therapeutics Inc. (NASDAQ: APGE) Right Now?
Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for APGE is 35.08M, and currently, short sellers hold a 13.10% ratio of that float. The average trading volume of APGE on April 19, 2024 was 705.90K shares.
APGE’s Market Performance
APGE’s stock has seen a -16.70% decrease for the week, with a -26.99% drop in the past month and a 50.20% gain in the past quarter. The volatility ratio for the week is 8.33%, and the volatility levels for the past 30 days are at 7.27% for Apogee Therapeutics Inc. The simple moving average for the past 20 days is -19.42% for APGE’s stock, with a 58.13% simple moving average for the past 200 days.
Analysts’ Opinion of APGE
Many brokerage firms have already submitted their reports for APGE stocks, with BTIG Research repeating the rating for APGE by listing it as a “Buy.” The predicted price for APGE in the upcoming period, according to BTIG Research is $43 based on the research report published on December 20, 2023 of the previous year 2023.
Wedbush, on the other hand, stated in their research note that they expect to see APGE reach a price target of $40. The rating they have provided for APGE stocks is “Outperform” according to the report published on August 08th, 2023.
APGE Trading at -7.42% from the 50-Day Moving Average
After a stumble in the market that brought APGE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.12% of loss for the given period.
Volatility was left at 7.27%, however, over the last 30 days, the volatility rate increased by 8.33%, as shares sank -27.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +34.53% upper at present.
During the last 5 trading sessions, APGE fell by -16.70%, in comparison to the 20-day moving average, which settled at $59.07. In addition, Apogee Therapeutics Inc. saw 73.05% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at APGE starting from Fairmount Funds Management LLC, who purchase 2,941,176 shares at the price of $17.00 back on Jul 13 ’23. After this action, Fairmount Funds Management LLC now owns 1,992,734 shares of Apogee Therapeutics Inc., valued at $49,999,992 using the latest closing price.
Shah Nimish P, the Director of Apogee Therapeutics Inc., purchase 1,750,000 shares at $17.00 during a trade that took place back on Jul 13 ’23, which means that Shah Nimish P is holding 1,750,000 shares at $29,750,000 based on the most recent closing price.
Stock Fundamentals for APGE
The total capital return value is set at -0.24.
Based on Apogee Therapeutics Inc. (APGE), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -36.76.
Currently, EBITDA for the company is -93.0 million with net debt to EBITDA at 1.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 19.38.
Conclusion
To put it simply, Apogee Therapeutics Inc. (APGE) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
